Sinclair Pharma PLC (SPH) Rating Reiterated by N+1 Singer
Sinclair Pharma PLC (LON:SPH)‘s stock had its “buy” rating reissued by research analysts at N+1 Singer in a report issued on Wednesday.
Other research analysts also recently issued reports about the company. Stifel Nicolaus increased their target price on Sinclair Pharma PLC from GBX 49 ($0.64) to GBX 63 ($0.82) and gave the company a “buy” rating in a research report on Wednesday, September 14th. Peel Hunt increased their target price on Sinclair Pharma PLC from GBX 66 ($0.86) to GBX 68 ($0.89) and gave the company a “buy” rating in a research report on Thursday, September 1st. Jefferies Group lowered their target price on Sinclair Pharma PLC from GBX 60 ($0.78) to GBX 55 ($0.72) and set a “buy” rating for the company in a research report on Wednesday, June 15th. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Sinclair Pharma PLC in a research report on Thursday, September 15th. Five research analysts have rated the stock with a buy rating, Sinclair Pharma PLC currently has an average rating of “Buy” and an average target price of GBX 57 ($0.74).
Shares of Sinclair Pharma PLC (LON:SPH) opened at 29.1999 on Wednesday. Sinclair Pharma PLC has a 52-week low of GBX 26.00 and a 52-week high of GBX 61.33. The stock has a 50 day moving average of GBX 29.02 and a 200-day moving average of GBX 32.05. The stock’s market capitalization is GBX 145.12 million.
About Sinclair Pharma PLC
Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.
Receive News & Stock Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related stocks with our FREE daily email newsletter.